secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0000950170-23-024258
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics director Lawrence Klein resigns; shareholders elect new directors and ratify auditor
--------------------------------------------------------------------------------

- Dr. Lawrence Klein resigned from Dyne Therapeutics board effective May 24, 2023, citing no disagreement with the company.
- Stockholders elected Joshua Brumm, David Lubner, and Jason Rhodes as Class III directors for three-year terms.
- Joshua Brumm received 35,497,922 votes for election; David Lubner received 32,530,452; Jason Rhodes received 28,522,828.
- Shareholders ratified Deloitte & Touche as independent auditor for fiscal year 2023 with 44,199,721 votes for, 2,413 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023024258/0000950170-23-024258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023024258/dyn-20230524.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-024258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer